The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders

Expert Opinion on Drug Discovery

Volumn 8, Issue 8, 2013, Pages 919-931

  Choi, Kee Hyun ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

Calcium channel inhibitors; Central nervous system disorders; Rational drug design; T type calcium channels

Indexed keywords

202 W 92; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL T TYPE; CALCIUM CHANNEL T TYPE INHIBITOR; CLOZAPINE; DILTIAZEM; ETHOSUXIMIDE; FLUNARIZINE; FLUOXETINE; FLUSPIRILENE; HALOPERIDOL; LAMOTRIGINE; MESUXIMIDE; MIBEFRADIL; NEUROLEPTIC AGENT; NIFEDIPINE; NORMESUXIMIDE; PENFLURIDOL; PHENYTOIN; PIMOZIDE; PYRIMIDINAMINE; SIPATRIGINE; TRAZODONE; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL; Z 944; ZONISAMIDE;

CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DRUG DESIGN; EPILEPSY; HUMAN; HYPERACTIVITY; INSOMNIA; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; TREMOR;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; HUMANS;

EID: 84880752150     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.796926     Document Type: Review

References (95)

1. Perez-Reyes E. Molecular physiology of low voltage-activated T-type calcium channels. Physiol Rev 2003;83(1):117-61
2. Crunelli V, Toth TI, Cope DW, et al. The window T-type calcium current in brain dynamics of different behavioural states. J Physiol 2005;562(Pt 1):121-9
3. Catterall WA, Perez-Reyes E, Snutch TP, et al. International union of pharmacology. XLVIII. nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005;57(4):411-25
4. Huguenard JR. Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 1996(58):329-48
5. Cueni L, Canepari M, Adelman JP, et al. Ca2+ signaling by T-type Ca2+ channels in neurons. Pflugers Arch 2009;457(5):1161-72
6. Anderson MP, Mochizuki T, Xie J, et al. Thalamic CaV3.1 T-type Ca2+ channel plays a crucial role in stabilizing sleep. Proc Natl Acad Sci USA 2005;102(5):1743-8
7. Sotty F, Danik M, Manseau F, et al. Distinct electrophysiological properties of glutamatergic, cholinergic and GABAergic rat septohippocampal neurons: Novel implications for hippocampal rhythmicity. J Physiol 2003;551(Pt 3):927-43
8. Bal T, McCormick DA. Synchronized oscillations in the inferior olive are controlled by the hyperpolarization-activated cation current Ih. J Neurophysiol 1997;77(6):3145-56
9. Krahe R, Gabbiani F. Burst firing in sensory systems. Nat Rev Neurosci 2004;5(1):13-23
10. Carbone E, Giancippoli A, Marcantoni A, et al. A new role for T-type channels in fast "low-threshold" exocytosis. Cell Calcium 2006;40(2):147-54
11. Lory P, Bidaud I, Chemin J. T-type calcium channels in differentiation and proliferation. Cell Calcium 2006;40(2):135-46
12. Kim D, Song I, Keum S, et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha1G T-type Ca2+ channels. Neuron 2001;31(1):35-45
13. Choi S, Na HS, Kim J, et al. Attenuated pain responses in mice lacking CaV3.2 T-type channels. Genes Brain Behav 2007;6(5):425-31
14. Zamponi GW, Lory P, Perez-Reyes E. Role of voltage-gated calcium channels in epilepsy. Pflugers Arch 2010;460(2):395-403
15. Todorovic SM, Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol 2011;163(3):484-95
16. Zhang Y, Vilaythong AP, Yoshor D, et al. Elevated thalamic low-voltage-activated currents precede the onset of absence epilepsy in the SNAP25-deficient mouse mutant coloboma. J Neurosci 2004;24(22):5239-48
17. Broicher T, Kanyshkova T, Meuth P, et al. Correlation of T-channel coding gene expression, IT, and the low threshold Ca2+ spike in the thalamus of a rat model of absence epilepsy. Mol Cell Neurosci 2008;39(3):384-99
18. Bidaud I, Mezghrani A, Swayne LA, et al. Voltage-gated calcium channels in genetic diseases. Biochim Biophys Acta 2006;1763(11):1169-74
19. Su H, Sochivko D, Becker A, et al. Upregulation of a T-type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci 2002;22(9):3645-55
20. Becker AJ, Pitsch J, Sochivko D, et al. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. J Neurosci 2008;28(49):13341-53
21. Faas GC, Vreugdenhil M, Wadman WJ. Calcium currents in pyramidal CA1 neurons in vitro after kindling epileptogenesis in the hippocampus of the rat. Neuroscience 1996;75(1):57-67
22. Chen Y, Lu J, Pan H, et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003;54(2):239-43
23. Heron SE, Khosravani H, Varela D, et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol 2007;62(6):560-8
24. Vitko I, Bidaud I, Arias JM, et al. The I-II loop controls plasma membrane expression and gating of CaV3.2 T-type Ca2+ channels: A paradigm for childhood absence epilepsy mutations. J Neurosci 2007;27(2):322-30
25. Ernst WL, Zhang Y, Yoo JW, et al. Genetic enhancement of thalamocortical network activity by elevating a1G-mediated low-voltage-activated calcium current induces pure absence epilepsy. J Neurosci 2009;29(6):1615-25
26. Gomora JC, Daud AN, Weiergraber M, et al. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001;60(5):1121-32
27. Crunelli V, Leresche N. Block of thalamic T-type Ca(2+) channels by ethosuximide is not the whole story. Epilepsy Curr 2002;2(2):53-6
28. Coulter DA, Huguenard JR, Prince DA. Differential-effects of petit-mal anticonvulsants and convulsants on thalamic neurons - calcium current reduction. Br J Pharmacol 1990;100(4):800-6
29. Todorovic SM, Perez-Reyes E, Lingle CJ. Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants. Mol Pharmacol 2000;58(1):98-108
30. Twombly DA, Yoshii M, Narahashi T. Mechanisms of calcium channel block by phenytoin. J Pharmacol Exp Ther 1988;246(1):189-95
31. McNaughton NC, Hainsworth AH, Green PJ, et al. Inhibition of recombinant low-voltage-activated Ca(2+) channels by the neuroprotective agent BW619C89 (Sipatrigine). Neuropharmacol 2000;39(7):1247-53
32. Hainsworth AH, McNaughton NC, Pereverzev A, et al. Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents. Eur J Pharmacol 2003;467(1-3):77-80
33. Caputi L, Hainsworth AH, Lavaroni F, et al. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. Brain Res 2001;919(2):259-68
34. Uebele VN, Nuss CE, Fox SV, et al. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys 2009;55(2):81-93
35. Tringham E, Powell KL, Cain SM, et al. T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. Sci Transl Med 2012;4(121):121ra19
36. Kraus RL, Li Y, Gregan Y, et al. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther 2010;335(2):409-17
37. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992;7(4):261-84
38. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31(9):1991-2001
39. Enyeart JJ, Biagi BA, Mlinar B. Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. Mol Pharmacol 1992;42(2):364-72
40. Santi CM, Cayabyab FS, Sutton KG, et al. Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 2002;22(2):396-403
41. Choi KH, Rhim H. Inhibition of recombinant CaV3.1 a1G T-type calcium channels by the antipsychotic drug clozapine. Eur J Pharmacol 2010;626(2-3):123-30
42. Traboulsie A, Chemin J, Kupfer E, et al. T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol Pharmacol 2006;69(6):1963-8
43. Matthews EA, Dickenson AH. Effects of ethosuximide, a T-type Ca2+ channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol 2001;415(2-3):141-9
44. Jagodic MM, Pathirathna S, Joksovic PM, et al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 2008;99(6):3151-6
45. Messinger RB, Naik AK, Jagodic MM, et al. In vivo silencing of the CaV3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain 2009;145(1-2):184-95
46. Latham JR, Pathirathna S, Jagodic MM, et al. Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice. Diabetes 2009;58(11):2656-65
47. Chen WK, Liu IY, Chang YT, et al. CaV3.2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain. J Neurosci 2010;30(31):10360-8
48. Wen XJ, Li ZJ, Chen ZX, et al. Intrathecal administration of CaV3.2 and CaV3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion. Acta Pharmacol Sin 2006;27(12):1547-52
49. Bourinet E, Alloui A, Monteil A, et al. Silencing of the CaV3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005;24(2):315-24
50. Takahashi T, Aoki Y, Okubo K, et al. Upregulation of CaV3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. Pain 2010;150(1):183-91
51. Todorovic SM, Lingle CJ. Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: Effects of anticonvulsant and anesthetic agents. J Neurophysiol 1998;79(1):240-52
52. Dogrul A, Gardell LR, Ossipov MH, et al. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 2003;105(1-2):159-68
53. Barton ME, Eberle EL, Shannon HE. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol 2005;521(1-3):79-85
54. Kim D, Park D, Choi S, et al. Thalamic control of visceral nociception mediated by T-type Ca2+ channels. Science 2003;302(5642):117-19
55. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004;109(1-2):150-61
56. Todorovic SM, Jevtovic-Todorovic V, Mennerick S, et al. CaV3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide. Mol Pharmacol 2001;60(3):603-10
57. Joksovic PM, Brimelow BC, Murbartian J, et al. Contrasting anesthetic sensitivities of T-type Ca2+ channels of reticular thalamic neurons and recombinant CaV3.3 channels. Br J Pharmacol 2005;144(1):59-70
58. Orestes P, Bojadzic D, Lee J, et al. Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway. J Physiol 2011;589(Pt 1):135-48
59. Pathirathna S, Brimelow BC, Jagodic MM, et al. New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5a-reduced neuroactive steroids. Pain 2005;114(3):429-43
60. Pathirathna S, Todorovic SM, Covey DF, et al. 5 alpha-reduced neuroactive steroids alleviate thermal and mechanical hyperalgesia in rats with neuropathic pain. Pain 2005;117(3):326-39
61. Todorovic SM, Pathirathna S, Brimelow BC, et al. 5 beta-reduced neuroactive steroids are novel voltage-dependent blockers of T-type Ca2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. Mol Pharmacol 2004;66(5):1223-35
62. Miwa H, Kondo T. T-type calcium channel as a new therapeutic target for tremor. Cerebellum 2011;10(3):563-9
63. Krack P, Benazzouz A, Pollak P, et al. Treatment of tremor in Parkinsons disease by subthalamic nucleus stimulation. Mov Disord 1998;13(6):907-14
64. Bucher SF, Seelos KC, Dodel RC, et al. Activation mapping in essential tremor with functional magnetic resonance imaging. Ann Neurol 1997;41(1):32-40
65. Miwa H, Koh J, Kajimoto Y, et al. Effects of T-type calcium channel blockers on a Parkinsonian tremor model in rats. Pharmacol Biochem Behav 2011;97(4):656-9
66. Park YG, Park HY, Lee CJ, et al. CaV3.1 is a tremor rhythm pacemaker in the inferior olive. Proc Natl Acad Sci USA 2010;107(23):10731-6
67. Handforth A, Homanics GE, Covey DF, et al. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology 2010;59(6):380-7
68. Miwa H, Hama K, Kajimoto Y, et al. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat Disord 2008;14(1):33-6
69. Gomez-Mancilla B, Latulippe JF, Boucher R, et al. Effect of ethosuximide on rest tremor in the MPTP monkey model. Mov Disord 1992;7(2):137-41
70. Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study. Neurology 2007;68(1):45-50
71. Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007;22(2):279-82
72. Xiang Z, Thompson AD, Brogan JT, et al. The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinsons disease. ACS Chem Neurosci 2011;2(12):730-42
73. Yang ZQ, Barrow JC, Shipe WD, et al. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem 2008;51(20):6471-7
74. Cueni L, Canepari M, Lujan R, et al. T-type Ca2+ channels, SK2 channels and SERCAs gate sleep-related oscillations in thalamic dendrites. Nat Neurosci 2008;11(6):683-92
75. Crunelli V, Cope DW, Hughes SW. Thalamic T-type Ca2+ channels and NREM sleep. Cell Calcium 2006;40(2):175-90
76. Crunelli V, Hughes SW. The slow The slow (1 Hz) rhythm of non-REM sleep: A dialogue between three cardinal oscillators Nat Neurosci 2010 13 1 9-17
77. Lee J, Kim D, Shin HS. Lack of delta waves and sleep disturbances during non-rapid eye movement sleep in mice lacking alpha1G-subunit of T-type calcium channels. Proc Natl Acad Sci USA 2004;101(52):18195-9
78. Takahashi H, Yoshimoto M, Higuchi H, et al. Different effects of L-type and T-type calcium channel blockers on the hypnotic potency of triazolam and zolpidem in rats. Eur Neuropsychopharmacol 1999;9(4):317-21
79. Graef JD, Huitt TW, Nordskog BK, et al. Disrupted thalamic T-type Ca2+ channel expression and function during ethanol exposure and withdrawal. J Neurophysiol 2011;105(2):528-40
80. Wiggins WF, Graef JD, Huitt TW, et al. Ethosuximide reduces ethanol withdrawal-mediated disruptions in sleep-related EEG patterns. Alcohol Clin Exp Res 2012
81. Dreyfus FM, Tscherter A, Errington AC, et al. Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of IT window. J Neurosci 2010;30(1):99-109
82. Mathes C, Friis S, Finley M, et al. QPatch: The missing link between HTS and ion channel drug discovery. Comb Chem High Throughput Screen 2009;12(1):78-95
83. Choi KH, Song C, Cheong CS, et al. Pharmacological studies of CaV3.1 T-type calcium channels using automated patch-clamp techniques. Gen Physiol Biophys 2011;30(1):100-5
84. Belardetti F, Tringham E, Eduljee C, et al. A fluorescence-based highthroughput screening assay for the identification of T-type calcium channel blockers. Assay Drug Dev Technol 2009;7(3):266-80
85. Xie X, Van Deusen AL, Vitko I, et al. Validation of high throughput screening assays against three subtypes of CaV3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev Technol 2007;5(2):191-203
86. Giordanetto F, Knerr L, Wallberg A. T-type calcium channels inhibitors: A patent review. Expert Opin Ther Pat 2011;21(1):85-101
87. Ijjaali I, Barrere C, Nargeot J, et al. Ligand-based virtual screening to identify new T-type calcium channel blockers. Channels (Austin) 2007;1(4):300-4
88. Doddareddy MR, Choo H, Cho YS, et al. 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem 2007;15(2):1091-105
89. Walsh CP, Davies A, Butcher AJ, et al. Three-dimensional structure of CaV3.1: Comparison with the cardiac L-type voltage-gated calcium channel monomer architecture. J Biol Chem 2009;284(33):22310-21
90. Lipkind GM, Fozzard HA, Hanck DA. A molecular model of the inner pore of the Ca2+ channel in its open state. Channels (Austin) 2011;5(6):482-8
91. Bergson P, Lipkind G, Lee SP, et al. Verapamil block of T-type calcium channels. Mol Pharmacol 2011;79(3):411-19
92. Lipkind GM, Fozzard HA. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel. Mol Pharmacol 2003;63(3):499-511
93. Cheng RC, Tikhonov DB, Zhorov BS. Structural model for phenylalkylamine binding to L-type calcium channels. J Biol Chem 2009;284(41):28332-42
94. Tikhonov DB, Zhorov BS. Structural model for dihydropyridine binding to L-type calcium channels. J Biol Chem 2009;284(28):19006-17
95. Tikhonov DB, Zhorov BS. Molecular modeling of benzothiazepine binding in the L-type calcium channel. J Biol Chem 2008;283(25):17594-604 Fusion Research Program